Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB

Core Insights - The article emphasizes the expertise of Terry Chrisomalis in the Biotech sector, highlighting his background in Applied Science and his focus on generating long-term value in Healthcare [2]. Group 1: Company Overview - Terry Chrisomalis operates the Biotech Analysis Central service, which provides in-depth analysis of various pharmaceutical companies [1]. - The service includes a library of over 600 Biotech investing articles and a model portfolio featuring more than 10 small and mid-cap stocks, each with detailed analysis [2]. Group 2: Subscription Details - The Biotech Analysis Central service is priced at $49 per month, with a promotional offer of a 33.50% discount for annual subscriptions, bringing the yearly cost to $399 [1].